中性粒细胞/淋巴细胞比值及血小板/淋巴细胞比值对弥漫性大B细胞淋巴瘤预后评估的价值
[Value of Neutrophil/Lymphocyte Ratio and Platelet/Lymphocyte Ratio for Prognostic Evaluation of Diffuse Large B-cell Lymphoma].
作者信息
Ni Jing, Wang Yong-Qing, Zhang Ying-Ping, Wu Wei, Zeng Qing-Shu, Yang Ming-Zhen, Xia Rui-Xiang
机构信息
Department Of Hematology, The First Affiliated Hospital of AnHui Medical University, Hefei 230032, Anhui Province, China.
Department Of Hematology, The First Affiliated Hospital of AnHui Medical University, Hefei 230032, Anhui Province, China. E-mail:
出版信息
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016 Apr;24(2):427-32. doi: 10.7534/j.issn.1009-2137.2016.02.022.
OBJECTIVE
To investigate the predictive value of neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) for the patients with diffuse large B-cell lymphoma (DLBCL).
METHODS
The clinical data of 57 DLBCL patients admitted in the First Affiliated hospital of Anhui Medical University were analyzed retrospectively. According to ROC curve, the cut-off value for NLR and PLR was deterimined, and the patients were divided into high and low NLR/PLR groups before first chamotherapy. Then the relation of NLR and PLR with overall survival (OS) and progression-free survival (PFS) was analyzed by univariate and multivariate COX regression.
RESULTS
The optimal cut-off value for NLR and PLR was 2.915 and 270.27, respectively. NLR at the diagnosis was found to be an independent predictor for OS and PFS by univariate and multivariate analysis, while the PLR was an independent predictor for PFS, but did not affect the OS.
CONCLUSION
NLR and PLR may provide additional prognostic information for DLBCL patients.
目的
探讨中性粒细胞/淋巴细胞比值（NLR）和血小板/淋巴细胞比值（PLR）对弥漫性大B细胞淋巴瘤（DLBCL）患者的预测价值。
方法
回顾性分析安徽医科大学第一附属医院收治的57例DLBCL患者的临床资料。根据ROC曲线确定NLR和PLR的截断值，并在首次化疗前将患者分为NLR/PLR高、低组。然后通过单因素和多因素COX回归分析NLR和PLR与总生存期（OS）和无进展生存期（PFS）的关系。
结果
NLR和PLR的最佳截断值分别为2.915和270.27。单因素和多因素分析发现，诊断时的NLR是OS和PFS的独立预测因素，而PLR是PFS的独立预测因素，但不影响OS。
结论
NLR和PLR可能为DLBCL患者提供额外的预后信息。
Zotero 插件